Chronic Pain Treatment Market is projected to witness substantial growth over the next few years, driven by advancements in treatment modalities and increasing awareness of the condition. The pipeline for Chronic Pain Therapeutics includes promising candidates that aim to not only treat acute attacks but also prevent recurrence.
DelveInsight’s “Chronic Pain Market Insights, Epidemiology and Market Forecast – 2034” report delivers an in-depth understanding of the Chronic Pain, historical and forecasted epidemiology as well as the Chronic Pain market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.
Unlock detailed insights into the Chronic Pain Market by downloading the comprehensive report from DelveInsight @ Chronic Pain Treatment Market Size
Key Takeaways from the Chronic Pain Market Report
- In October 2024- Novartis Pharmaceuticals- The purpose of this study is to evaluate efficacy, safety and tolerability of secukinumab in Chinese patients with active nr-axSpA. Treatment difference of secukinumab 150mg vs. placebo in Chinese nr-axSpA patients in terms of ASAS 40 response rate as well as safety profile will be provided by the study.
- According to the Centers for Disease Control and Prevention an estimated 20.4% (50.0 million) of US adults had chronic pain and 8.0% of US adults (19.6 million) had high-impact chronic pain, with higher prevalences of both chronic pain and high-impact chronic pain reported among women, older adults, previously but not currently employed adults, adults living in poverty, adults with public health insurance, and rural residents.
- As per a study by Zelaya et al. (2020), the percentage of adults who had chronic pain in the past 3 months increased with age and was higher among those aged 45–64 (25.8%) and 65 and over (30.8%) compared with those aged 18–29 (8.5%) and 30–44 (14.6%). Similarly, the percentage of adults who had high-impact chronic pain in the past 3 months increased with age and was also higher among those aged 45–64 (10.3%) and 65 and over (11.8%) compared with those aged 18–29 (2.2%) and 30–44 (4.4%).
- The Chronic Pain Companies such as AbbVie, Paradigm Biopharmaceuticals Ltd., Noven Pharmaceuticals, Pfizer, Anika Therapeutics, Biogen, Tonix Pharmaceuticals, Taiwan Liposome Company, Centrexion Therapeutics, Braeburn Pharmaceuticals, Regeneron, Teva Pharmaceuticals, Mitsubishi Tanabe Pharma Corporation, Vertanical GmbH, and others.
- Promising Chronic Pain Therapies such as Secukinumab, AbobotulinumtoxinA, Rexlemestrocel-L + HA mixture, IncobotulinumtoxinA, Retatrutide, and others.
Gain a competitive edge in the Chronic Pain Market by exploring our in-depth analysis. Visit our website to access the full report and make informed strategic decisions @ Chronic Pain Treatment Drugs
Chronic Pain Epidemiology Segmentation in the 7MM
- Total Chronic Pain Prevalent Cases
- Total Chronic Pain Diagnosed Cases
- Chronic Pain Severity-specific Cases
- Chronic Pain Age-specific Cases
- Chronic Pain Cause-specific Cases
Chronic Pain Market Insights
Pain management requires a tailored approach to each individual and context and is multimodal and interdisciplinary, requiring trained healthcare providers and a coordinated, comprehensive, integrated response. Reducing pain is one of the ultimate goals of chronic pain management but not the leading goal. Medical practitioners should manage chronic pain while trying to minimize AEs induced by the treatment, and it is important to improve the patient’s quality of life, and Activities of Daily Living (ADLs) actions.
Discover key developments and opportunities in the Chronic Pain Market. Click here to learn more from DelveInsight’s latest report @ Chronic Pain Market Size
Chronic Pain Marketed Drugs
- JOYCLU (diclofenac etalhyaluronate sodium): Seikagaku Corporation/Chiltern International
JOYCLU is a formulation in which hyaluronic acid and diclofenac (an anti-inflammatory drug) are chemically bound using Seikagaku’s proprietary technology. It is designed to release diclofenac by hydrolysis in the joint. Improvement of symptoms of osteoarthritis (knee joint and hip joint) is expected by administering JOYCLU into the joint cavity once every 4 weeks. JOYCLU is the first joint function improvement agent in Japan to treat osteoarthritis of the hip joint.
- ZILRETTA (triamcinolone acetonide extended-release injectable suspension): Pacira BioSciences
ZILRETTA (triamcinolone acetonide extended-release injectable suspension) is an intra-articular injection to manage osteoarthritis pain in the knee. ZILRETTA is Flexion’s novel, proprietary, sustained-release formulation composed of triamcinolone acetonide (TA) embedded in a biodegradable PLGA matrix that extends residence time in the joint for the treatment of mild-to-moderate OA of the knee. ZILRETTA received approval from the FDA on October 2017.
Chronic Pain Emerging Drugs
- ZILOSUL (pentosan polysulfate sodium): Paradigm Biopharmaceuticals.
Pentosan polysulfate sodium (PPS) is a semi-synthetic drug manufactured from the wood chips of European beech trees. Extracted glucuronoxylans are sulfated to produce a negatively charged product that mimics glycosaminoglycans (GAGs). GAGs are complex carbohydrates that play a regulatory role in the body through interacting with proteins involved with inflammation. Key features of PPS activity are its anti-inflammatory and tissue regenerative properties, as well as its mild anti-thrombotic activity.
- TNX-102 SL: Tonix Pharmaceuticals
TNX-102 SL, a sublingual tablet with 2.8 mg of cyclobenzaprine HCl, is taken nightly to treat fibromyalgia. Its rapid absorption and reduced production of a long-lasting active metabolite enhance its effectiveness. This patented formulation optimizes cyclobenzaprine delivery to improve sleep quality and minimize residual effects. TNX-102 SL, a centrally-acting analgesic, eases pain by enhancing sleep. It’s currently in mid-Phase III development for fibromyalgia management.
Chronic Pain Drugs Market
Currently, several types of medications are being used in the management of chronic pain, including acetaminophen, ibuprofen, aspirin, COX-2 inhibitors, antimigraine medications, sedatives, opioids, and antidepressants. Nonpharmacologic treatments for chronic pain can include exercise, physical therapy, counseling, electrical stimulation, biofeedback, acupuncture, hypnosis, chiropractic medicine, and other treatments. There are several approved drugs for the treatment of chronic pain such as EMGALITY (galcanezumab-gnlm), AIMOVIG (erenumab), and AJOVY (fremanezumab), among others.
Download DelveInsight’s Chronic Pain Market report today and stay ahead in this rapidly evolving field. @ Chronic Pain Clinical Trials
Scope of the Chronic Pain Market Report
- Coverage- 7MM
- Chronic Pain Companies- AbbVie, Paradigm Biopharmaceuticals Ltd., Noven Pharmaceuticals, Pfizer, Anika Therapeutics, Biogen, Tonix Pharmaceuticals, Taiwan Liposome Company, Centrexion Therapeutics, Braeburn Pharmaceuticals, Regeneron, Teva Pharmaceuticals, Mitsubishi Tanabe Pharma Corporation, Vertanical GmbH, and others.
- Chronic Pain Therapies- Secukinumab, AbobotulinumtoxinA, Rexlemestrocel-L + HA mixture, IncobotulinumtoxinA, Retatrutide, and others.
- Chronic Pain Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
- Chronic Pain Unmet Needs, KOL’s views, Analyst’s views, Chronic Pain Market Access and Reimbursement
Download the report to understand which factors are driving Chronic Pain Market Trends @ Chronic Pain Market Trends
Table of Content
1 Key Insights
2 Report Introduction
3 Chronic Pain Market Overview at a Glance
4 Executive Summary of Chronic Pain
5 Key events
6 Disease Background and Overview
7 Epidemiology and Patient Population
8 Patient Journey
9 Marketed Products
10 Emerging Therapies
11 Chronic Pain: The Seven Major Markets Analysis
12 SWOT Analysis
13 Unmet Needs
14 KOL Views
15 Market Access and Reimbursement
16 Appendix
17 DelveInsight Capabilities
18 Disclaimer
19 About DelveInsight
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/